Human IFN-γ T cell ELISPOT antibody pair - 20-plate

SKU
CT640-20
Validated ELISPOT antibody pair; reagents available separately (1920 determinations).
Format
20-plate
Price
€ 1,160
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ
Description
Our ELISPOT antibody pairs are validated for high assay performance using the same reagents and materials included in U-CyTech ELISPOT kits. These antibody pairs are optimized for reliable and reproducible ELISPOT assays.
The antibody pairs are available in convenient 10-plate and 20-plate format, providing 960 or 1920 determinations, respectively.
Compatible reagents for ELISPOT assays can be purchased separately, allowing customization of your ELISPOT workflow.
Description
IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor responses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.
Alternative names
IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon
Image

References

Authors, et al. Title Journal Year Volume Pages
Dominique Bertrand Early BK Polyomavirus-Specific Immunity and Viral Clearance Kidney Int Rep 2026 11 107064
Xing Zhang Long-term results of multi-antigen stimulated cell therapy-I, alone or in combination with chemotherapy, as first-line maintenance therapy in advanced sarcoma: a multicenter, phase 1 trial Clin Cancer Res 2026
Boukje Maarse Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response-A Randomized, Placebo-Controlled Trial Clin Pharmacol Ther 2026 120 1049-1056
Alexandra Serris Prognostic Value of Aspergillus-Specific T Cells in Invasive Pulmonary Aspergillosis Among Patients with Hematologic Malignancies J Infect Dis 2026
Fanny Alby-Laurent Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study Vaccine 2026 74 128130
Gerrit Koopman Adenoviral vector oropharyngeal spray immunization elicits mucosal immunity and protects against heterologous SARS-CoV-2 infection NPJ Vaccines 2025 10 267
M Stammes Comparative Study of [18F]DPA714 and [18F]FDG PET Tracers in an Experimental Model of Pulmonary Tuberculosis Mol Imaging Biol 2025 27 943-953
Micha Ronner Profiling a Neo-Antigen-Driven Immune Response in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study of the KLH Challenge Model Clin Pharmacol Ther 2025 118 1132-1142
Benjamin Schrijver Anti-retinal immune response in sarcoid uveitis: A potential role for PCLO as an antigenic target J Autoimmun 2025 151 103375
Bandar Alosaimi A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine J Med Virol 2025 97 e70071